Weight-Loss Injections Could Cut Sick Days in Half and Relieve Pressure on the NHS
New research reveals GLP-1 weight-loss jabs slashed sickness absence by nearly 50%, while also reducing GP visits and A&E attendance significantly.
Weight-Loss Jabs Show Remarkable Impact on Workplace Absences and NHS Demand
Groundbreaking new research suggests that weight-loss injections could dramatically reduce sickness-related absences from work and ease mounting pressure on an already stretched National Health Service. The findings point to a potentially transformative role for GLP-1 medications beyond simple weight management.
Key Findings From the UK Study
A UK-based study tracking 1,270 NHS patients over a nine-month period found that those prescribed GLP-1 injections experienced a 45% drop in sick days overall, while extended absences lasting five days or more declined by 56%. All participants were enrolled in Oviva's tier 3 weight management programme and had been prescribed the injections alongside at least three obesity-related health conditions — most frequently anxiety, high blood pressure, and type 2 diabetes.
The research, unveiled at the European Congress on Obesity held in Istanbul, also revealed a significant reduction in how often patients needed to consult their doctors. Face-to-face GP appointments fell by an average of 43%, while remote consultations dropped by 48%. Notably, more than 60% of participants reported no GP contact whatsoever during the study period.
Potential to Free Up Millions of GP Appointments
A separate analysis involving 738 patients prescribed the jabs found that A&E visits within the group fell by 25%. Experts suggest that if access to GLP-1 treatments were expanded to the estimated 3.4 million people currently eligible for weight-loss medications on the NHS, the health service could reclaim nearly 10 million GP appointments annually — generating savings of approximately £364 million per year, which equates to close to 3% of the GP core budget.
With roughly 30% of adults in England classified as obese, the scale of potential benefit is substantial.
Martin Fidock, UK Managing Director of Oviva, commented: "Britain is in the grip of a productivity crisis, and obesity is one of the biggest drivers. Our data shows that when people get the right treatment — jabs combined with proper clinical support — they don't just lose weight. They get back to work, stop relying on their GP and start living again."
Policy Experts Call Findings 'Striking'
Dr Charlotte Refsum, Director of Policy at the Tony Blair Institute, described the results as particularly compelling. "Broader access to anti-obesity medications could deliver significant gains for the economy alongside major savings for the NHS," she said. "This study brings that to life in the real world — showing not just substantial weight loss, but fewer GP visits and more people staying in work."
Additional Benefits: Asthma and Migraines
Two separate Danish studies, also presented at the same conference, indicated that GLP-1 medications may offer benefits well beyond weight loss.
The first study found that patients living with asthma alongside overweight, obesity, or type 2 diabetes who were treated with semaglutide or liraglutide experienced a 26% reduction in asthma exacerbations — including hospitalisations — compared to the previous year. Inhaler usage dropped by 14%, and daily inhaled corticosteroid exposure fell by 23%. Pneumonia events were also reduced by 10%. Crucially, these effects emerged within just one month of beginning GLP-1 treatment, before any significant weight loss had taken place.
The second Danish study focused on younger adults aged 18 to 35 receiving Wegovy for weight management. Results showed an 18% reduction in the use of acute migraine triptan medication among this group. Researchers noted that further investigation is required to understand dosage effects and whether similar outcomes can be replicated across other GLP-1 medications.
A Turning Point for Obesity Treatment?
Collectively, these findings strengthen the case for wider NHS access to GLP-1 weight-loss treatments. Beyond helping patients shed excess weight, the drugs appear to deliver measurable improvements in workplace productivity, reduce the burden on primary and emergency care, and potentially alleviate a range of serious conditions. As the evidence base continues to grow, pressure is likely to mount on health authorities to broaden eligibility and invest further in these medications.
